Drug Hunter

Name: Drug Hunter
Address: Palo Alto, CA, US
Telephone: +16504587087
Price range: Not Applicable

A trusted, independent source of curated, factual information for the drug discovery community.

09/03/2026

Iberdomide Receives Accelerated FDA Approval for Multiple Myeloma as the First CELMoD | https://drughunters.com/466ZqIf

Iberdomide (Zenbexus®), a CRBN-mediated molecular glue degrader of IKZF1 (Ikaros) and IKZF3 (Aiolos), received accelerated FDA approval for the treatment of multiple myeloma in August 2026, representing the first CELMoD in an new era for the IMiD class of drugs.

The essential role that IKZF1 and IKZF3 play in blood and immune cell development makes their over-activation a central part of plasma cell malignancies—and the degradation of these proteins has been clinically validated therapeutic strategy in multiple myeloma.

Check out our profile on iberdomide’s development to learn:
- The historical context of IKZF degraders in hematological malignancies
- The biological rationale for iberdomide’s development for treatment of lupus and multiple myeloma
- Key clinical results, including the approval-enabling surrogate endpoint

Read more on Drug Hunter: https://drughunters.com/466ZqIf

09/02/2026

Structure's Oral GLP-1 Contender Aleniglipron Gears Up for Ph. 3 | https://drughunters.com/4zN0yhL

Structure Therapeutics’ aleniglipron is a small-molecule GLP-1R agonist designed to bring incretin-like efficacy into a more scalable, oral format.

The molecule is entering a competitive landscape shaped by injectable blockbusters such as semaglutide and tirzepatide, an approved oral formulation of semaglutide, and emerging oral small-molecule contenders including Chugai/Eli Lilly’s orforglipron.

Recent Ph. 2b ACCESS data showed clinically meaningful weight loss, with no apparent plateau at week 36 and continued weight reductions in the open-label extension.

The key question now is whether aleniglipron can differentiate not only on efficacy, but also on tolerability as Structure advances toward Ph. 3.

Read our updated profile on aleniglipron here: https://drughunters.com/4zN0yhL

09/01/2026

Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
https://drughunters.com/3T7pCzx
Thursday, September 10th, 2026
8 AM PT | 11 AM ET | 5 PM CET

Small molecule drug discovery requires the balance of several factors such as potency, PK, safety, and developability. However, the profiles of clinically successful molecules are often broader than conventional optimization guidelines might suggest.

In this Flash Talk, Dean Brown, Senior Vice President and Head of Discovery Sciences at Jnana Therapeutics, will present an analysis of 104 oral small molecule drugs approved by the FDA between 2020 and 2024, examining approved dose regimens, human PK, safety, and DDI. He will highlight examples of successful drugs with properties that fall outside of traditional expectations and discuss how these can help medicinal chemists better understand the risks and tradeoffs that can be tolerated in the design of future small-molecule medicines.

Sign up now to hear more about the lessons learned from recently approved small molecules: https://drughunters.com/4qNDprr

08/31/2026

Molecules of the Month – July 2026 | https://drughunters.com/4i5wLdQ

Drug Hunter’s July picks spotlight Artios Pharma’s ART6043, an oral, allosteric Polθ inhibitor designed to exploit homologous recombination defects; Eli Lilly’s LY3410738, a covalent, dual mutant IDH1/2 inhibitor built to address acquired resistance mutations; and Roche’s nivegacetor (RG6289), a γ-secretase modulator that lowers pathogenic Aβ42 without broad γ-secretase enzymatic inhibition.

Read the full article to explore the molecules that made our July 2026 list.

Full article: https://drughunters.com/4i5wLdQ

08/29/2026

This month’s Drug Hunter Patent Gazette showcases five cutting-edge drug discovery disclosures:

- Kymera’s first disclosure of its CRBN-mediated IRF5 degraders
- AlzeCure’s gamma-secretase modulators that likely underpin the recent deal with Eli Lilly
- Nxera’s potent BLT2 agonists, which could have applications in inflammation or wound healing
- Gilead’s set of phosphate prodrugs that enhance the bioavailability of their PARP7 inhibitors
- Insilico Medicine’s GR antagonists look to pivot a validated oncology target to pain indications

From insights into potential first-in-class clinical candidates to reevaluating validated targets for new indications, across a broad range of therapeutic areas, these disclosures cover a diverse array of biological pathways and modalities.

Read the July 2026 Patent Gazette on Drug Hunter: https://drughunters.com/3UGp6sI

08/28/2026

AI agents are often discussed in the context of molecular design, but is that where they’ll have the greatest impact on drug discovery?

Rather than molecular design, the greatest near-term opportunity for agentic AI may instead lie in automating knowledge- and time intensive-tasks—including data QC, gathering relevant literature, and identifying competitor programs—freeing drug hunters to spend more time on experimental design, hypothesis generation, and creative thinking.

We review emerging benchmarks evaluating general purpose AI agents on real scientific workflows, discuss where they already outperform conventional LLMs, and examine the practical limitations—including hallucinations, citation reliability, paywalls, privacy, and the continued need for human validation—that still limit their broad adoption.

Members can read the full article here: https://drughunters.com/4zJKJsi

08/27/2026

In a milestone moment for metastatic PDAC (pancreatic ductal adenocarcinoma) treatment, Revolution Medicines’ daraxonrasib (Rasonque®) has been FDA-approved for previously treated metastatic forms of the cancer.

RAS has occupied a unique position in drug discovery and development. While it is central to oncology biology and clinically important—>90% of pancreatic cancer patients harbor RAS mutations—it has proven exceptionally challenging to drug. Daraxonrasib is an oral tri-complex molecular glue pan-RAS(ON) inhibitor designed to suppress GTP-bound RAS signaling across multiple mutants and wild-type RAS isoforms, and has fundamentally changed how the community thinks about the future of RAS-targeted therapies.

Check out our recently updated case study to find out why daraxonrasib was selected as the 2025 Drug Hunter Molecule of the Year, including:

- Why broad-spectrum RAS inhibition could be the next chapter in RAS-targeting drug discovery
- How structural elements of the compound impart its pan-RAS activity and predicted high barrier to resistance
- Key clinical successes that enabled the drug to receive Breakthrough Therapy designation and a National Priority Voucher from the FDA

Check out the full article on Drug Hunter: https://drughunters.com/4xyPK5p

08/26/2026

ACS Fall 2026 – First Time Disclosures | Open Access Article | https://drughunters.com/45PDkdm

The structures are here.

The First Time Disclosures sessions at ACS Fall 2026 in Chicago unveiled 13 small molecule programs spanning oncology, immunology, infectious diseases, dermatology, kidney and liver disease, and obesity.

Organized by the ACS MEDI Division and chaired by H. Rachel Lagiakos, the sessions featured:

- QuantaTherapeutics – QTX3034: a G12D-preferring, multi-KRAS allosteric inhibitor for pancreatic and colorectal cancers
- AcertaPharma / AstraZeneca – AZD3632: a menin inhibitor for myeloid malignancies
- Novartis – KFA115: a dual IKZF2/IKZF4 molecular glue degrader for advanced cancers
- Schrödinger – SGR-3515: a dual Wee1/Myt1 inhibitor for advanced solid tumors
- GenFleetTherapeutics – GFH647: a non-covalent BTK inhibitor for B cell malignancies
- VentusTherapeutics – VENT-03: a cGAS inhibitor for systemic and cutaneous lupus
- Pfizer – PF-07905428: a topical ACC inhibitor for acne vulgaris
- DeepAppleTherapeutics – DAT-003: an MRGPRX2 antagonist for mast cell-driven diseases
- BlueprintMedicines / Sanofi– BLU-808: a wild-type KIT inhibitor for chronic urticaria
- FimbrionTherapeutics / GSK – GSK3882347: a bacterial FimH antagonist for uncomplicated UTIs
- MazeTherapeutics – MZE829: an APOL1 inhibitor for APOL1-mediated kidney disease
- RectifyPharmaceuticals – RTY-406: a dual ABCB4/BSEP positive functional modulator for primary sclerosing cholangitis
- Pfizer – PF-07976016: a GIPR antagonist developed for obesity

Check out the full article for a preview of the therapeutic rationale, mechanisms of action, discovery highlights, and—of course—the structures behind each of these newly disclosed compounds.

Read more: https://drughunters.com/45PDkdm

08/25/2026

New coverage area: oligonucleotide therapeutics!

Bepirovirsen, GSK/Ionis Pharmaceuticals’ investigational A*O (antisense oligonucleotide) that targets HBV mRNA, achieved a 19% functional cure rate in Ph. 3 hepatitis B trials.

Interestingly, its efficacy is not solely reliant on HBV mRNA knockdown.

Evidence suggests bepirovirsen stimulates an immune response, a key differentiator from other programs, with broader implications for oligonucleotide drug discovery.

The drug was recently approved in Japan (Hibsago®) and is currently under FDA review for the treatment of chronic hepatitis B.

Members can read the full article here: https://drughunters.com/45JW51O

08/24/2026

Oligonucleotide therapeutics have progressed from an interesting concept to a validated drug modality, but their success has depended as much on advances in chemistry. This cheatsheet explores how modifications to the base, sugar, backbone, and conjugates have shaped today's FDA-approved oligonucleotides.

Members can read the full article here: https://drughunters.com/4cXtrOm

Address

Palo Alto, CA

Telephone

+16504587087

Website

https://drughunter.com/

Alerts

Be the first to know and let us send you an email when Drug Hunter posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Drug Hunter:

Want your business to be the top-listed Clothing Store in Palo Alto?